Table 1 Clinicopathological features of the 69 patients with primary breast carcinomas according to methylation status of CXCL12 and ESR1 genes
Variables | Samples (%) | CXCL12methylation(a) | p a | CXCL12methylation(b) | p b | ESR1methylation(c) | p c | |||
|---|---|---|---|---|---|---|---|---|---|---|
M (%) | U (%) | M (%) | U (%) | M (%) | U (%) | |||||
Age | ||||||||||
< 45 | 9 (13) | 0 | 9 (100) | 0.3378 | 3 (33) | 6 (67) | 0.2853 | 2 (22) | 7 (78) | 0.2937 |
≥ 45 | 60 (87) | 10 (17) | 50 (83) | 34 (56.7) | 26 (43.3) | 26 (43) | 34 (57) | |||
Stage | ||||||||||
I | 13 (19.7) | 2 (15.4) | 11 (84.6) | 5 (38.5) | 8 (61.5) | 1 (7.7) | 12 (92.3) | |||
II | 31 (47) | 5 (16.1) | 26 (83.9) | 0.9691 | 13 (42) | 18 (58) | 0.3696 | 10 (32.3) | 21 (67.7) | 0.0003 |
III/IV | 22 (33.3) | 3 (14) | 19 (86) | 13 (59.1) | 9 (40.9) | 16 (72.7) | 6 (27.3) | |||
Tumour size | ||||||||||
pT1 | 19 (27.6) | 4 (21) | 15 (79) | 10 (53) | 9 (47) | 4 (21) | 15 (79) | |||
pT2 | 36 (52.2) | 4 (11.1) | 32 (88.9) | 0.6088 | 17 (47.2) | 19 (52.8) | 0.3034 | 13 (36.1) | 23 (63.9) | 0.0029 |
pT3/pT4 | 14 (20.2) | 2 (14.3) | 12 (85.7) | 10 (71.4) | 4 (28.6) | 11 (78.6) | 3 (21.4) | |||
SBR | ||||||||||
I | 19 (27.6) | 4 (21.1) | 15 (78.9) | 7 (36.8) | 12 (63.2) | 2 (11) | 17 (89) | |||
II | 33 (47.8) | 4 (12) | 29 (88) | 0.4178 | 17 (39.4) | 16 (60.6) | 0.0180 | 14 (42.4) | 17 (57.6) | 0.0011 |
III | 17 (24.6) | 2 (11.8) | 15 (88.2) | 13 (65) | 4 (35) | 12 (71) | 5 (29) | |||
Lymph node status | ||||||||||
Positive | 35 (51.5) | 5 (14.3) | 30 (85.7) | 1.0000 | 22 (63) | 13 (37) | 0.2231 | 19 (54.3) | 16 (45.7) | 0.0288 |
Negative | 33 (48.5) | 5 (15.1) | 28 (84.9) | 15 (45.4) | 18 (54.6) | 9 (27.3) | 24 (72.7) | |||
Estrogen receptor | ||||||||||
Positive | 57 (83.8) | 7 (12.2) | 50 (87.8) | 0.6312 | 29 (51) | 28 (49) | 0.2084 | 19 (33) | 38 (67) | 0.0054 |
Negative | 11 (16.2) | 2 (18.2) | 9 (81.8) | 8 (73) | 3 (27) | 9 (81.8) | 2 (18.2) | |||
HER2 | ||||||||||
Positive | 20 (31.3) | 5 (25) | 15 (75) | 0.0955 | 12 (60) | 8 (40) | 0.5996 | 10 (50) | 10 (50) | 0.4249 |
Negative | 44 (68.7) | 3 (6.9) | 41 (93.1) | 23 (52.3) | 21 (47.7) | 17 (38.6) | 27 (61.4) | |||
Progesterone receptor | ||||||||||
Positive | 45 (65) | 7 (17) | 38 (83) | 1.0000 | 25 (56) | 20 (44) | 1.0000 | 16 (36) | 29 (64) | 0.0808 |
Negative | 16 (35) | 2 (12.5) | 14 (87.5) | 9 (56.3) | 7 (43.7) | 10 (62.5) | 6 (37.5) | |||
Metastasis | ||||||||||
Positive | 15 (22.4) | 3 (20) | 12 (80) | 0.4075 | 14 (93) | 1 (7) | 0.0008 | 13 (86.7) | 2 (13.3) | < 0.0001 |
Negative | 52 (77.6) | 6 (11.5) | 46 (88.5) | 23 (44) | 29 (56) | 14 (26.9) | 38 (73.1) | |||
Recurrence | ||||||||||
Positive | 8 (12) | 2 (25) | 6 (75) | 0.3413 | 6 (75) | 2 (25) | 0.2700 | 4 (50) | 4 (50) | 0.7049 |
Negative | 59 (88) | 8 (13.5) | 51 (86.5) | 30 (51) | 29 (49) | 23 (39) | 36 (61) | |||
Death | ||||||||||
Positive | 17 (26) | 4 (23.5) | 13 (76.5) | 0.2250 | 15 (88) | 2 (12) | 0.0019 | 13 (76.5) | 4 (23.5) | 0.0013 |
Negative | 48 (74) | 5 (10.4) | 43 (89.6) | 21 (43.7) | 27 (56.3) | 14 (37.8) | 33 (62.2) | |||
Histological type | ||||||||||
IDC | 51 (73.9) | 8 (15.7) | 43 (84.3) | 1.0000 | 30 (58.8) | 21 (41.2) | 0.1759 | 20 (39.2) | 31 (60.8) | 0.7829 |
ILC | 18 (26.1) | 2 (11.1) | 16 (88.9) | 7 (39) | 11 (61) | 8 (44.4) | 10 (55.6) | |||